Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2004

View Archived Issues

Increased survival found in multiple myeloma patients treated with erythropoietin

In vivo detection of antiangiogenic activity of SU-6668 by enhanced MRI technique

Greater benefits associated with intensive lipid-lowering therapy after acute coronary syndrome

Pulmonary hypertension and increased mortality in sickle cell disease

New antibody program in Centocor/MorphoSys collaboration

Phase II program under way for extended-release Sonata

Novavax comments on findings of estrogen-alone arm of WIH study

Preclinical neurochemical profile of sarizotan, a dual 5-HT1A agonist and D2 antagonist

Complete genome of S. erythracea sequenced

Patent notice of allowance for Zestra

Vical's CMV vaccine efforts supported by NIAID grants

Astex Technology and Boehringer Ingelheim enter drug discovery alliance

Compound Therapeutics confirms acquisition of Phylos

NOX-100 produces positive results in phase I/IIa septic shock study

New phase IIb trial evaluates alagebrium chloride for systolic hypertension

New tryptase inhibitors emerge from Altana R&D

New fatty acid-camptothecin conjugates developed at Panorama

Two series of antiangiogenic macrolides designed by Mercian and Eisai scientists

Aventis claims three series of eNOS upregulators

Kyoto Pharmaceutical presents new inhibitors of ACAT and lipid peroxidation

Novel RdRp inhibitors discovered by Micrologix researchers

Novel CCK1 antagonists and their use reported by Rotta

Paxene receives European approval for metastatic breast and ovarian cancers

New Panzem formulation studied in phase I trial

New Lotronex dosage available

Topical PMX-53 improves psoriasis lesion scores in pilot study

NMED-160 enters clinical testing

Positive results reported from phase Ib/IIa trial of Hemospan

Presentation of new Riquent data

Iquix receives FDA approval for bacterial corneal ulcer

Elan achieves key R&D milestones during 2003

Additive neuroprotection of creatinine and COX-2 inhibitors in ALS transgenic mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...